A critical advance in cancer study is occurring with the use of mini-antibodies to reactivate dysfunctional p53. This vital malignant inhibitor protein is frequently disabled in many kinds of tumors, resulting https://bookmarkindexing.com/story21826186/mini-antibodies-reactivate-tumor-suppressor-p53-new-potential-pathway-for-cancer-management